Unaudited Financial Results 31-12-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.0 pts less than Nifty Microcap 250 and 6.7 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Crestchem Ltd reported Q3 FY26 revenue from operations of Rs 715.82 lakhs, up 49.2% YoY from Rs 479.59 lakhs in Q3 FY25, driven by its single Nutrition-Speciality Chemicals segment. For the nine months ended Dec 2025, revenue grew 8.6% YoY to Rs 1,938.21 lakhs. Q3 profit after tax jumped 37.6% YoY to Rs 71.71 lakhs, but 9M PAT actually fell about 24% to Rs 161.31 lakhs from Rs 211.61 lakhs, as total expenses rose faster than revenue. EBITDA margins clearly compressed, with 9M operating margin slipping from roughly 16% to around 11%, reflecting higher material and employee costs. Q3 EPS stood at Rs 2.39. The statutory auditor issued an unqualified (clean) limited review report.
Short-term, the strong 49% Q3 revenue jump and PAT growth are positive, but the 24% drop in 9M profits and clear margin compression indicate rising costs that investors should watch closely. Mixed signals — likely neutral to mildly negative on the stock until cost pressures ease.